KLRK1 and neoplasm: In another study including 30 NSCLC patients, NK cells ranged between 1.7% and 34.4% of tumor infiltrating lymphocytes, most being CD56dim, and associated with downregulation of activating receptors such as CD16 and NKG2D [47].